David Altshuler - 10 Feb 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Global Research and CSO
Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
10 Feb 2022
Transactions value $
-$1,376,206
Form type
4
Filing time
14 Feb 2022, 15:11:13
Previous filing
03 Feb 2022
Next filing
16 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Tax liability -$836K -3.52K -5.35% $237.74 62.2K 10 Feb 2022 Direct
transaction VRTX Common Stock Sale -$197K -841 -1.35% $233.92 61.3K 11 Feb 2022 Direct F1, F2, F3
transaction VRTX Common Stock Sale -$178K -757 -1.23% $234.95 60.6K 11 Feb 2022 Direct F1, F3, F4
transaction VRTX Common Stock Sale -$142K -601 -0.99% $236.28 60K 11 Feb 2022 Direct F1, F3, F5
transaction VRTX Common Stock Sale -$23.2K -98 -0.16% $237.23 59.9K 11 Feb 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1.
F2 Open market sales reported on this line occurred at a weighted average price of $233.92 (range $233.36 to $234.30).
F3 Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4 Open market sales reported on this line occurred at a weighted average price of $234.95 (range $234.47 to $235.28).
F5 Open market sales reported on this line occurred at a weighted average price of $236.28 (range $235.84 to $236.74).